9-ING-41 in Patients With Advanced Cancers
Cancer · Pancreatic Cancer · Sarcoma · Renal Cancer · Refractory Cancer · Refractory Neoplasm · Refractory Non-Hodgkin Lymphoma · Pancreatic Adenocarcinoma · Resistant Cancer · Neoplasm Metastasis · Neoplasm of Bone · Neoplasm, Breast · Neoplasm of Lung · Neoplasms,Colorectal · Neoplasms Pancreatic · Malignant Glioma · Malignancies · Malignancies Multiple · Bone Metastases · Bone Neoplasm · Bone Cancer · Pancreas Cancer · Pancreatic Neoplasms · Breast Neoplasms · Acute T Cell Leukemia Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 350 (planned)
- Started
- Jan 4, 2019
- Main results expected
- Jun 2026
- Fully finished
- Jun 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
Measured over: 3 months to 3 years
Part 3 Arm B
Measured over: 3 months to 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03678883 · record last updated 2026-04-03 · checked 2026-11-09 15:36 UTC